$RKLB

Spice Adam C. sold $8.8M of RKLB

Spice Adam C. (Chief Financial Officer) sold 140,157 shares of Rocket Lab Corp (RKLB) at an average of $62.63 ($62.26–$62.97, $8.78M total) across 2 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Spice Adam C.
Published Sep 4, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RKLB
Bearish
medium confidence
Mentioned
$RKLB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RKLBBearishMed
01

Why it matters

The CFO's sale reduces his ownership to ~1.16M shares, potentially influencing investor perception.

02

Market read

Insider sell of $8.8M is a material event for RKLB, likely affecting short-term price action.

03

What to watch

The sale was pre-arranged under a 10b5-1 plan, reducing negative signaling.

Relevance 5/10Novelty 6/10Timing: post-market filing on 2026-09-04

Background

Form 4 filing discloses insider transactions required by SEC, providing transparency on executive holdings.

Company-level read

Ticker impact

$RKLBBearishMedium confidence
Context

CFO Spice Adam C. sold 140,157 shares for $8.78M via a 10b5-1 plan, reducing his stake.

Expected impact

Possible short-term price dip as market absorbs the large insider sale.

Evidence & confidence

The sale size ($8.8M) is material for a mid-cap; insider sales often trigger sell pressure.

Market effects

May raise concerns for the aerospace/space launch sector if multiple insiders sell.

Limited to US investors; no broader regional effect.

Low global impact; primarily affects Rocket Lab shareholders.

Counterpoint

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Rocket Lab Corp

    US-listed aerospace company (NASDAQ:RKLB).

  • Spice Adam C.

    Chief Financial Officer of Rocket Lab.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RKLBHigh

Rocket Lab (RKLB) Stock Drops After Neutron Rocket Launch Delay

Rocket Lab (RKLB) shares fell 7.9% during trading and 7.3% after-hours after delaying its Neutron rocket launch to 2027 due to manufacturing issues. The company's P/S ratio is 45.17, above historical and industry averages, reflecting high growth expectations. Insider selling totaled $683.3 million over the past year. Rocket Lab has a GF Score of 77/100, indicating strong financial health but weak profitability.

$RKLBMed

Rocket Lab pushes Neutron rocket's debut flight to 2027, shares fall

Rocket Lab announced a delay in the debut flight of its Neutron rocket to 2027, pushing back from the previously targeted fourth quarter of 2026. The news caused the company's shares to drop about 6% in extended trading. Neutron is a reusable medium-lift rocket aimed at competing for larger commercial and national-security missions. Recently, Rocket Lab secured a multi-year launch agreement for 20 missions with Tokyo-based Synspective.

$RKLBHigh

Why is Rocket Lab stock tumbling today?

Rocket Lab (RKLB) stock dropped 7.2% in after-hours trading after delaying its Neutron rocket launch to 2027 due to manufacturing issues. The company also faces insider-selling pressure and a challenging macro environment with rising Fed rate hike bets. The stock is down over 60% from its 52-week high.

$RKLBHigh

Rocket Lab Stock Stumbles Despite Big Space Ambitions

Rocket Lab USA (RKLB) shares fell 8% during and after trading due to CEO Peter Beck's planned stock sale, SpaceX funding concerns, and a delay in the Neutron rocket launch to 2027. Despite record Q2 revenue of $234M and a strong backlog, investors worry about integration risks and profitability. Analysts maintain a Strong Buy rating with a $104.44 price target.